Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
Rollins
Gina
G
D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D018890:Chemoprevention; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
D016588:Anticarcinogenic Agents; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride